LatestIP And Trademarks 13 November 2026
Moleculin Secures Australian Patent for Annamycin Formulation
Moleculin Biopharma has been granted an Australian patent for its Annamycin formulation, adding to an extensive portfolio that already includes patents in the United States, Canada, China, Europe, India, Israel, Japan, Mexico, Singapore and Taiwan. The new protection strengthens the company’s intellectual‑property position ahead of upcoming clinical milestones.
Moleculin Biopharma announced the grant of an Australian patent covering its Annamycin formulation.
- Expands a global patent portfolio that already spans the US, Canada, China, Europe, India, Israel, Japan, Mexico, Singapore and Taiwan.
- Enhances the company's IP strength as it moves toward later‑stage trials.
Read the full report here.
Need help understanding this update?
Connect with our domain experts instantly via WhatsApp for customized legal guidance.